Brenes CLA, Montenegro QE

Language: Spanish
References: 17
Page: 165-170
PDF size: 189.86 Kb.

ABSTRACT

Serum tumor markers are often used for the evaluation of the response and follow-up of oncologic patients after different dispensed therapies. Tumor markers, also called biological markers or biomarkers, are defined as molecules, substances or processes that are qualitatively or quantitatively altered as a result of a precancerous condition or cancer, detectable by laboratory testing in blood, body fluids or in tissues. The nature of the tumor markers is highly variable, ranging from nucleic acid, DNA or RNA, a protein or peptide, to complex processes such as an antibody, apoptosis and proliferation. There is no ideal tumor marker, defined as those with a sensitivity and specificity of 100%. Tumor markers may be used for screening people with risk of developing cancer, for early detection of confined and potentially curable disease, as part of the diagnosis, the differential diagnosis, as a prognostic and predictive value test, as a tool to assess the treatment administered, and for the detection of relapse if the patient has a new opportunity for treatment before clinical manifestations reappear.

REFERENCES

1. 2010©.American Society of Clinical Oncology (ASCO). Understanding Tumor Markers. Accessed at www.cancer.net/patient/ All+About+Cancer/Cancer.Net+Features/Treatments%2C+Tests%2C+

2. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.J Gastrointest Oncol 2012;3(2):105-119. DOI: 10.3978/j. issn.2078-6891.2011.021

3. Befeler AS, DiBisceglie AM. Hepatocellulart carcinoma: diagnosis and treatment. Gastroenterology 2002; 122:1609-1619.

4. Benson AB 3rd, Desch CE, Flynn PJ, et al.: 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 18 (20): 3586-8, 2000.

5. Campuzano-Maya, G. Utilidad clínica de los marcadores tumorales. Medicina & Laboratorio 2010; 16: 411-445. Módulo 1 (La clínica y el laboratorio), número82. Editora Médica Colombiana S.A.,

6. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14 (10): 2843-77, 1996.

7. Desch CE, Benson AB 3rd, Smith TJ, et al.: Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 17 (4): 1312, 1999.

8. Diamandis EP. Tumor markers: Past, present, and future. In: Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications edited by Diamandis EP, Fritsche HA, Lilja H,Chan DW, Schwartz MK. Washington, D. C.: AACC Press, 2002, p. 3-8.

9. Filella X, Molina R, Grau JJ, et al.: Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 216 (1): 55- 9, 1992.

10. Granados, M.2010. manual de oncología procedimientos médico quirúrgicos cuarta edición. Mc Graw Hill. D.F, México.134-136.

11. Izumi R, Shimizu K, Kiriyama M, et al.: Alpha-fetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J Surg Oncol 49 (3): 151-5, 1992

12. Lechner P,Lind P, Goldenberg DM: Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival? J Am Coll Surg 191 (5): 511-8, 2000.

13. Lonneux M, Reffad AM, Detry R, et al.: FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 29 (7): 915-21, 2002

14. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2002; 55:74-108.

15. Rosen M, Chan L, Beart RW Jr, et al.: Follow-up of colorectal cancer: a metaanalysis. Dis Colon Rectum 41 (9): 1116-26, 1998.

16. Stillwagon GB, Order SE, Guse C, et al.: Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01. Int J Radiat Oncol Biol Phys 20 (1): 65- 71, 1991.

17. Willett CG, Daly WJ, Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172 (4): 350-2, 1996.